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ABSTR ACT: Everolimus combined with exemestane is an important treatment option for patients suffering from estrogen receptor-positive, human 
epidermal growth factor receptor 2-negative, advanced breast cancer (ABC) who have been previously treated with a nonsteroidal aromatase inhibitor 
(NSAI). After presentation of phase III registration trial BOLERO-2, several phase IIIb trials have been started to evaluate this regimen in a more real-world 
setting. Here, we review the efficacy and safety data published or presented at selected international meetings. These studies confirmed the  outcome observed 
in the BOLERO-2 trial. Patient acceptance rate is also discussed by focusing on the permanent everolimus discontinuation rate in these trials. Factors 
influencing the safety profile are also reported, including the impact of age. The optimal sequence of combined therapy approaches associating targeted 
and endocrine therapy (ET) has yet to be determined as new treatment options such as cyclin-dependent kinase inhibitors become available. However, 
everolimus–exemestane remains an important treatment option with a major impact on progression-free survival (PFS) and an acceptable safety profile.
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Introduction
BOLERO-2 was a key phase III randomized trial.1,2 It used 
the mammalian target of rapamycin (mTOR) inhibitor, evero-
limus, in association with exemestane as a valid treatment 
option in postmenopausal women with estrogen receptor 
(ER)-positive, human epidermal growth factor receptor 2 
(HER2)-negative, advanced breast cancer (ABC) progress-
ing after a nonsteroidal aromatase inhibitor (NSAI).3,4 The 
progression-free survival (PFS) more than doubled in those 
metastatic patients if everolimus is combined with exemes-
tane. However, all international guidelines indicate that this 
choice must consider the toxicities encountered with this 
treatment.3,4
The safety profile of everolimus is a widely debated topic. 
Clinicians may fear this therapeutic option especially in light 
of the overall survival (OS) data in BOLERO-2. While the 
trial was not powered for this endpoint, there were no sta-
tistically significant differences.5 The goal of our review is to 
compare the most relevant and real-life data for efficacy and 
safety of everolimus in ABC. Indeed, patients in registration 
trials are usually younger with fewer comorbidities and come-
dications and enrolled at highly selected anticancer centers. 
Consequently, it is important that the result can be confirmed 
in a less selected patient population. We will also look for 
some factors influencing toxicities. With a good selection of 
patients and a careful management of adverse events (AEs), 
this treatment is beneficial for patients suffering from meta-
static disease and delays the use of chemotherapy (CT).
Recently, this drug combination and the advent of cyclin-
dependent kinase inhibitors such as palbociclib have radically 
changed the treatment strategy of patients presenting ER-
positive ABC. The current therapeutic approaches restore 
sensitivity to endocrine therapy (ET) and delay the use of CT 
except in patients presenting symptomatic visceral disease. 
Additional therapeutic weapons are under development in 
ongoing phase III registration trials. Thus, as more targeting 
agents become available, a good selection of patients and care-
ful management of specific AE are of considerable interest. 
The optimal initial treatment modality and the best sequential 
use of targeted agents combined with ET are now important 
open questions. The efficacy, side effects, and costs have to be 
integrated when defining the optimal treatment sequence.
mTOR Inhibitors: Mechanism of Action
The phosphatidylinositol-3-kinase (PI3K)–protein kinase B 
(AKT)–mTOR signaling pathway is a key regulator of cell 
survival, proliferation, and angiogenesis. Preclinical data 
showed that there are effectors of the mTOR pathway includ-
ing some protein kinases that phosphorylate different targets 
and control protein translocation. The subunit alpha of the ER 
is one of these targets. Thus, it facilitates crosstalk between 
the ER pathway and the PI3K–AKT–mTOR pathway.6,7 
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The hyperactivation of the PI3K–AKT–mTOR pathway fol-
lowing, for example, loss of phosphatase and tensin homolog 
(PTEN) or phosphatidylinositol-3-kinase catalytic alpha 
polypeptide (PIK3CA)-activating mutations can lead to a 
ligand-independent activation of the ER signaling pathway. 
This could partly explain the resistance to ET in these cancers 
with hyperactivation of the PI3K-AKT-mTOR pathway. This 
is a rational use of an mTOR inhibitor in ET-resistant breast 
cancers (BCs).8
Everolimus: Pharmacological Data
Everolimus is a rapamycin analog that inhibits the mTORC1 
cellular complex. This leads to pleomorphic and ubiquitari-
ous actions such as inhibition of cell proliferation, angiogen-
esis, protein synthesis, and metabolic dysregulation.9 Its peak 
plasma concentration is obtained between one and two hours 
after a single oral dose following oral daily administration. 
One week is necessary to reach the steady state. The plasma 
protein binding is about 74%. The metabolization is hepatic. 
The elimination half-life is from 18 to 35 hours, but this may 
be delayed in patients with hepatic failure.10,11
Everolimus is a substrate for CYP3A4, CYP3A5, CYP2C8, 
and P-glycoprotein. Thus, many drug interactions can modify 
plasmatic concentrations of everolimus and affect its efficacy 
and toxicity.10 The patient’s characteristics such as age, sex, or 
weight do not appear to affect the pharmacokinetic properties 
of everolimus.10
Everolimus: Efficacy Data in ABC
Some phase II studies have confirmed this hypothesis. The first 
one evaluated the safety and efficacy of oral everolimus alone in 
two different schedules in minimally pretreated patients with 
metastatic breast cancer (BC). This showed a clinical activity 
of the oral 10 mg daily therapy.9 The response rate was 12%.12 
The second was a neoadjuvant setting and explored whether 
sensitivity to letrozole was enhanced with everolimus.13 The 
response rate by clinical palpation in the everolimus arm was 
significantly higher than that with letrozole alone.13 The third 
study evaluated the efficacy and safety of everolimus in combi-
nation with tamoxifen in patients with metastatic BC resistant 
to aromatase inhibitors and suggested a better outcome with 
the combination versus tamoxifen alone.14 These preliminary 
results encouraged the realization of international multicenter 
phase III studies (Table 1).
Everolimus: the BOLERO 2 trial. The key efficacy 
data on everolimus in ABC were reported in the BOLERO-2 
trial.3–5 The study met its primary endpoint. It demonstrated 
a statistically significant benefit in PFS for the association 
of everolimus–exemestane versus placebo–exemestane for 
patients with ER-positive ABC who relapsed or progressed 
during or shortly after NSAI therapy. The median PFS was 
more than doubled with 3.2 months in the placebo group and 
7.8 months in the everolimus group4 (hazard ratio (HR) = 0.45; 
95% confidence interval (CI) = 0.38–0.54). The data on OS 
were a secondary endpoint and did not meet statistical signifi-
cance but with the addition of everolimus to exemestane, the 
OS increased by 4.4 months.5 However, this sample size was 
based on PFS, and the study was powered only with an eight-
month OS improvement.5 These results are the cornerstone of 
international guidelines regarding everolimus in ABC.
Longer median PFS has been observed in the BOLERO-2 
trial in both treatment arms in patients presenting better per-
formance status, fewer sites of metastatic disease, no visceral 
disease (or bone-only disease), having received no prior CT, 
or no prior CT for advanced disease. This was also true in 
younger patients (under 65 years) and in patients receiving 
first-line therapy for advanced disease.2
Two other BOLERO trials have already been published 
in a different patient population with HER2-positive ABC. 
They hypothesized that the inhibition of mTOR could enhance 
trastuzumab sensitivity. BOLERO-1 evaluated the efficacy 
and safety of adding everolimus to trastuzumab and pacli-
taxel as first-line treatment for patients with HER2-positive 
ABC. It did not meet its primary endpoint, which was a gain 
in PFS.15 Interestingly, in the ER-negative subpopulation, the 
median PFS increased from 13.1 to 20.3 months (HR = 0.66; 
95% CI = 0.48–0.91), but the protocol-specified significance 
threshold (P = 0.0044) was not crossed. BOLERO-3 evalu-
ated the efficacy and safety of adding everolimus to trastu-
zumab and vinorelbine in patients with trastuzumab-resistant 
ABC who had previously received a taxane therapy.16 It met 
its primary endpoint with a gain in PFS of 1.22 months 
with everolimus (HR = 0.78; 95% CI = 0.65–0.95), but this 
benefit is not clinically meaningful.16 Based on these data, 
everolimus is not recommended in HER2-positive ABC. 
Nevertheless, an exploratory analysis combining biomarker 
data from BOLERO 1 and BOLERO 3 suggests that patients 
with HER2-positive ABC suffering from tumors presenting 
PIK3CA mutations, PTEN loss, or a hyperactive PI3K path-
way could derive a PFS benefit from the addition of everolimus 
to trastuzumab and CT.17
There are two additional ongoing BOLERO trials in 
phase II. BOLERO-4 evaluates the safety and efficacy of 
adding everolimus to letrozole in the first-line setting of post-
menopausal patients with ER-positive ABC.18 BOLERO-6 is 
assessing the efficacy and safety of everolimus and capecitabine 
monotherapies versus everolimus–exemestane combination in 
patients with ER-positive ABC.19
Everolimus: prospective observational studies. Some 
other studies have confirmed the BOLERO-2 efficacy data. 
These real-world studies represent a broader patient popula-
tion than the BOLERO-2 trial with no limitations on the 
number of prior CT lines (except one study, EVEREXES, 
which is limited to one prior line), time of recurrence or pro-
gression after NSAI therapy, or prior exemestane therapy.
STEPAUT was presented at the European Breast Cancer 
Conference in Amsterdam by Steger et al in March 2016.20 This 
is an Austrian noninterventional study whose aim is to evaluate 
Everolimus in the treatment of breast cancer 
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efficacy and safety in patients treated with everolimus and 
exemestane according to clinical routine. Its enrollment is still 
ongoing. The analysis was recently presented on 134 patients. 
The median PFS is 9.23 months (95% CI  =  6.83–10.03), 
which is consistent with the results obtained in BOLERO-2. 
A subgroup analysis was made according to everolimus dos-
ing. Interestingly, PFS was lower for patients with 5  mg 
(4.97 months; 95% CI = 3.13–10.03) compared to 9.83 months 
with 10 mg (95% CI = 6.43–10.3). Patients receiving the 5 mg 
starting dose did have less favorable prognostic factors (more 
visceral metastases, worse eastern cooperative oncology group 
(ECOG) performance status, and more prior therapies). Only 
the 10 mg starting dose was prospectively evaluated, and this 
is the registered starting dose of everolimus.
The planned interim analysis of EVEREXES was pre-
sented at San Antonio Breast Cancer Symposium by Im et al in 
December 2015.21 It is a phase IIIb study of safety as primary 
endpoint and efficacy as secondary endpoint with enrollment 
of a poorly represented population in BOLERO-2-concerning 
patients from Asia Pacific, Africa, and Middle East. The 
analysis was made on 227 patients. The median PFS is 
9.45 months (95% CI = 7.4–9.9), which is also consistent with 
BOLERO-2.
The final efficacy analysis of 4EVER was also presented at 
the San Antonio Breast Cancer Symposium by Tesch et al in 
December 2015.22 This is a German phase IIIb study that aims 
to evaluate the efficacy and safety in a broader patient popula-
tion than BOLERO-2. This analysis was made on 281 patients. 
The efficacy was lower than BOLERO-2 with a median PFS of 
5.6 months (95% CI = 5.4–6). This can be partially explained 
by the patient population, which was more advanced and heav-
ily pretreated. A subgroup analysis showed a better efficacy of 
the everolimus–exemestane combination without prior CT 
(PFS 6.2 months; 95% CI = 5.6–7.7) compared to that with 
prior CT (PFS 5.2 months; 95% CI = 4.2–5.5).
Finally, the second interim analysis of BRAWO was 
presented at European Society of Medical Oncology by 
Fasching et al in September 2014.23 It is a German noninter-
ventional study. One of the primary endpoints was to extend 
the understanding of the efficacy of the combination treatment. 
This second interim analysis was made on 500 patients. The 
8-month median PFS was also consistent with BOLERO-2 
(95% CI = 6.7–9.1). The PFS was higher at 10.1 months in a 
subgroup analysis where the combination was used in the first-
line setting (95% CI = 6.7–17.6).
All these data confirm the considerable benefit in PFS 
obtained with the everolimus–exemestane combination. 
Combined with the safety data, we show that better selection 
of patients and careful management of AE would be beneficial 
to the majority of patients.
Everolimus: Safety Data in ABC
The safety profile of everolimus is clearly worse than the pla-
cebo. The frequency of AE is always higher in the everolimus 
group with more serious adverse events (SAEs), more dose 
interruptions or modifications, more discontinuations of 
treatment due to AE, and more on-treatment deaths. An 
important question is if this toxicity could be considered tol-
erable and manageable. A detailed analysis of the safety data is 
necessary for each patient to determine individually the risk/
benefit ratio of this treatment and the patient acceptance rate.
AEs are globally similar between all the trials published 
or presented until today (Tables 1–3). Most AEs are mild to 
moderate (grade 1/2). The most frequent AEs are stomatitis, 
diarrhea, rash, fatigue, nausea, decreased appetite, weight 
loss, cough, dyspnea, and anemia. The metabolic AEs—
hyperlipidemia and hyperglycemia—are of particular inter-
est because they may worsen cardiovascular comorbidities of 
postmenopausal women. Noninfectious pneumonitis (NIP) is 
less frequent, but can be life threatening. The most frequent 
grade 3/4 AEs are stomatitis, fatigue, diarrhea, hyperglyce-
mia, dyspnea, NIP, and anemia.
BOLERO-1. We emphasize two safety data issues. The 
first one is the relative dose intensity (RDI) of everolimus, 
which is clearly less than that in the other trials (everolimus 
RDI BOLERO-1 = 0.54). According to Hurvitz et al,15 the 
dose adjustments were more frequent because of the toxicity 
encountered from the combination with CT. The second one is 
the higher frequency of on-treatment deaths perhaps because 
of the limited experience with everolimus when used with 
paclitaxel and trastuzumab. Of note, there was a higher fre-
quency of on-treatment deaths in regions with limited experi-
ence with everolimus; in some cases, the protocol-defined AE 
management guidelines were not followed.15 This indicates a 
key point of everolimus treatment monitoring—careful man-
agement in experienced centers is required.
BOLERO-2. AEs were seen in all patients in the 
everolimus–exemestane arm and in 91% of patients in the 
placebo–exemestane arm.2 In this trial, it is important to 
consider treatment duration in the two arms. Indeed, in the 
everolimus–exemestane arm, the median duration of expo-
sure to everolimus was 23.9 weeks and the median exposure to 
exemestane was 29.5 weeks. This is longer than median exposure 
to exemestane in the placebo–exemestane arm (14.07 weeks).2 
This nearly doubled treatment duration and may partially con-
tribute to the higher incidences of AE, dose modifications, and 
treatment discontinuation among everolimus-treated patients. 
The majority of the AEs were resolved using protocol-defined 
management strategies. Stomatitis, NIP, and thrombocytope-
nia were the most common AEs leading to dose modifications 
in the everolimus–exemestane arm. The two most common 
AEs leading to treatment discontinuation in this arm were 
NIP and stomatitis.2,24
More than one-third of stomatitis events was reported in 
the first two weeks. A total of 97% of patients with grade 3 
stomatitis experienced resolution to grade 1 following dose 
interruption/reduction.2,24 The time course for pneumonitis 
differed from stomatitis with few early events and an increased 
Lousberg and Jerusalem
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number of events over time without seeing a plateau. A total of 
80% of patients with grade 3 pneumonitis experienced reso-
lution to grade 1 following dose interruption/reduction.2,24
Approximately half of all hyperglycemia/new-onset dia-
betes mellitus events occurred within the first six weeks.2,24 
More than one-third of fatigue events occurred within six 
weeks of treatment initiation. In all, 72% of patients with 
grade 3/4 fatigue in the experimental arm experienced reso-
lution to grade 1 following dose interruption/reduction.2,24 
Thus, the majority of class-effect AEs, except pneumonitis, 
had a relatively short time to onset with an incidence plateau 
thereafter.24
Grade 3/4 AEs were experienced by 41% of patients. They 
mostly resolved to grade 1 fairly rapidly following dose inter-
ruption/modification. Consequently, close follow-up in the 
first weeks of everolimus/exemestane treatment is indicated. 
Management recommendations for everolimus-related AEs 
(comprising dose interruptions/reductions) were included in 
the trial and facilitated continued treatment in most cases. The 
duration of dose interruptions/reductions was relatively short, 
and most patients who resumed the full dose (10 mg everoli-
mus) did so within two weeks to maintain dose intensity.24 Of 
note, 34% of patients in the everolimus–exemestane arm expe-
rienced a one-level dose reduction at 5 mg of everolimus daily.24
Moreover, BOLERO-2 included a health-related qual-
ity of life (HRQOL) analysis using the EORTC QLQ-C30 
as a secondary endpoint. This is one of the most common, 
well-developed, and validated instruments for measuring 
HRQOL in oncology trials.2,25 The EORTC QLQ-C30 
global health status scores were analyzed based on two defini-
tions of time to definitive deterioration (TDD): a protocol-
specified 5% change from baseline and a minimal important 
difference (MID) of a 10-point change from baseline. With 
the 5% change from baseline, the TDD of global health status 
was prolonged in patients who received everolimus–exemes-
tane (8.3 months) versus those receiving placebo–exemestane 
(5.8 months).25 Using the 10-point MID assessment, the dif-
ference in TDD between the two arms was similar with more 
profound benefits noted in patients with a baseline ECOG 
performance status of 1 or 2 and those aged 65 years.25 Thus, 
in light of these results, we can conclude that the patients in 
the experimental arm had a better quality of life than those 
in the placebo arm. This is particularly evident in younger 
patients and those with a reduced ECOG performance status 
at baseline.
BOLERO-3. The safety data in BOLERO-3 are of lim-
ited interest in our review. Indeed, everolimus was adminis-
tered at 5 mg daily.16 The actual recommended starting dose 
is 10 mg daily. Moreover, in combination with vinorelbine, the 
trial reports a high incidence of hematological AEs, especially 
leukoneutropenia.16 This does not allow a good safety analysis of 
everolimus with regard to the current approved regimen in BC.
BALLET. BALLET is a European phase IIIb, 
expanded-access multicenter trial that evaluated the safety of 
everolimus plus exemestane in a patient population similar to 
BOLERO-2.
BALLET is very interesting because it represents the 
largest ever reported safety dataset on a general patient popu-
lation. It also includes the largest safety dataset in an elderly 
subgroup (see below).
BALLET studied a more heavily pretreated patient pop-
ulation than BOLERO-2. The median follow-up was shorter 
in BALLET with 4.6 versus 17.7 months in BOLERO-2. 
Nevertheless, safety data in BALLET are quite similar to 
those in BOLERO-2.26 There are some differences. First, the 
incidence of stomatitis and NIP was lower in the BALLET 
trial. This may be attributed to the shorter median follow-up 
and the fact that some patients dropped out of the study but 
continued everolimus under reimbursement.26 Thus, the long-
term safety profile could not be evaluated in these patients. 
Another difference was the median everolimus treatment 
duration. It was shorter in BALLET than in BOLERO-2 
(16 vs. 23.9 weeks). In addition, the median RDI of evero-
limus was higher in the BALLET trial. This may be attrib-
utable to an improvement in treatment optimization with a 
lower rate of discontinuation due to AEs (17.1% in BALLET 
vs. 26.3% in BOLERO-2).26
Everolimus and Safety: Sequence Therapies in ABC
One can compare the administration of everolimus–exemes-
tane in the first-line setting with later lines of therapy.
BALLET. Median treatment duration is longer in patients 
who received the treatment as a first-line therapy (4.4 vs. 
3.7 months in the full population).26
Also, the incidence of everolimus-related AEs appear to 
be lower in the first-line setting versus later lines with less 
stomatitis (45.6% vs. 51.4%), rash (11.4% vs. 15.1%), asthenia 
(10.9% vs. 15.1%), and diarrhea (9.1% vs. 10.7%).26 Grade 3/4 
stomatitis (7.7% vs. 9.4%), diarrhea (0.5% vs. 0.9%), rash (0.5% 
vs. 1%), and NIP (0.9% vs. 1.9%) were also reported less fre-
quently in the first-line setting versus later lines.26
4EVER. There was no difference in the objective response 
rate (ORR) in the subset of patients with prior exemestane 
therapy.22 However, ORR was higher in patients without 
prior CT in the metastatic setting (11.5% without prior CT 
vs. 6.6% with prior CT).22 Similarly, there was no difference 
in median PFS in the subset of patients with prior exemestane 
therapy.22 However, PFS was longer in patients with no prior 
CT in the metastatic setting (6.2 months without prior CT vs. 
5.2 months with prior CT).22
BRAWO. The median PFS observed in the first 
500 patients was 8.0 months, which is inferior to the 
10.1 months median PFS observed in the subset of patients 
who received the combination everolimus–exemestane as first-
line therapy for advanced disease.23
First- or second-line–treated patients were less likely 
to experience any AE than those receiving everolimus–
exemestane in later-line setting.23
Everolimus in the treatment of breast cancer 
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Together, these data support the use of combination 
everolimus–exemestane as an early therapy for ABC.
Interestingly, a recent Italian retrospective trial was pub-
lished. It was conducted to evaluate the safety in an unselected 
population of 181 patients and the possible association of 
toxicities with previous treatments.27 Eligible patients were 
women with ABC ER-positive, HER2-negative, whose dis-
ease was refractory to previous inhibitor aromatase therapy. 
Prior CT regimens and anticancer endocrine therapies for 
advanced disease were allowed. The multivariate analysis did 
not show any association between the numbers of previous 
treatments neither the toxicity nor the response.27 Of note, 
an association was found between the previous anthracycline 
exposure and a toxicity equal to or greater than grade 2.27 
The authors interpret this result as a possible selection bias 
(patients heavily pretreated).
Everolimus and Safety: Selection of Patients in ABC
Older people are underrepresented in clinical trials, but they 
constitute a significant proportion of BC patients. BC inci-
dence rates in women aged 65 years or older are nearly two 
to three times greater than in younger women.28 They have 
more comorbidities than younger people, and clinicians can 
undertreat them. However, is any starting dose modification 
according to age justified?
BOLERO-2. In BOLERO-2, 164 of the 724 patients 
(22.7%) were aged 70 years or older.
The baseline performance status in this subgroup of 
patients was slightly worse, and these patients had more 
comorbidities and comedications than younger patients, 
resulting in an imbalance between age subgroups.2,29 The 
mean duration of everolimus exposure was 23.2 weeks in 
the elderly versus 33.8 weeks in the younger subgroup.29 
The median dose intensity of everolimus was 7.2 mg daily in 
elderly patients and 8.9 mg daily in the younger ones.29 Dose 
modifications (reductions/interruptions) were similar between 
the two age subgroups (66.8% in younger and 66.9% in older 
patients). However, a greater proportion of older patients 
discontinued everolimus–exemestane treatment because of 
AE than younger patients.29
The relative gain in PFS was similar in older and 
younger patients with a HR of 0.45 and 0.44, respectively 
(median PFS of 6.77 vs. 1.51 months in older patients; 
median PFS of 8.11 vs. 4.01 months in younger patients).29 
There was a lower incidence of stomatitis, rash, hypercholes-
terolemia, and liver enzyme increases in the elderly subsets 
receiving everolimus–exemestane than in younger subsets.29 
In contrast, the incidences of decreased appetite, dyspnea, 
anemia, asthenia, and increased creatinine levels were higher 
in elderly patients receiving everolimus–exemestane than in 
younger cohorts.29 The most frequent grade 3/4 AEs were 
similar in the two age subgroups. With the exception of 
stomatitis, rash, and diarrhea, their incidence was somewhat 
higher in the elderly.29
The time to deterioration in performance status was sim-
ilar between treatment arms in elderly patients. The reduc-
tion in performance status due to AE may be balanced by 
preservation of performance status as a result of longer dis-
ease control.29 After adjustment for treatment exposure, the 
incidence of on-treatment deaths due to AE was similar 
between the two treatment arms in younger patients but was 
higher in the everolimus–exemestane arm (7.7% vs. 0%) in the 
elderly.29 This may be attributable to preexisting comorbidi-
ties that were imbalanced between the two treatment arms 
in the elderly population (more vascular disorders, cerebro-
vascular accidents, anemia, and psychiatric disorders in the 
everolimus–exemestane arm at baseline).29
BALLET. The safety dataset in the elderly subgroup of 
BALLET is the largest ever reported with this regimen in 
this age group. Of the 2133 patients, there were 563 elderly 
patients (aged 70 years or older). This represents 26.4% of all 
patients in this trial.26 Everolimus was slightly more toxic in 
the elderly.
In the elderly, the median treatment duration was shorter 
(3.2 vs. 3.7 months in the full population); the median RDI 
was slightly lower (0.95 vs. 1 in nonelderly); and dose reduc-
tions (37.7% vs. 26.7%), interruptions (60.5% vs. 54.2%), and 
discontinuations (18.9% vs. 10.6%) due to AEs were higher 
than that in the younger subgroup.26 In the elderly subset, 
95.2% of patients experienced at least one AE (vs. 94.7% 
in the full population). The most common AEs across all 
grades were stomatitis (55.5% vs. 51.9% in nonelderly), asthe-
nia (28.5% vs. 20.7% in nonelderly), and decreased appetite 
(22.4% vs. 13.7% in nonelderly).26
The most frequent grade 3/4 AEs were stomatitis (12.3% 
vs. 8.3% non-elderly), asthenia (5.7% vs. 2.9% nonelderly), and 
hyperglycemia (4.6% vs. 2.3% in nonelderly). NIP was also 
slightly higher in elderly with 11.2% versus 8.9% in nonelderly 
patients.26 Treatment-related SAEs were reported in 10.3% of 
the elderly versus 7.8% of nonelderly patients.26 On-treatment 
deaths were also higher in the elderly: 6.9% vs. 5.7% in the full 
population.26
BRAWO. Subgroup analyses of the second interim anal-
ysis and longer median PFS durations were also seen in the 
following patient subgroups: Ki-67 expression 20%, bone-
only metastases, first-line therapy with longer recurrence-free 
interval, and no prior CT.30
The third interim analysis was presented at european 
society of medical oncology (ESMO) in 2015 and focused on 
the  correlation of patient characteristics and treatment dura-
tion.31 Age, ECOG performance status, body mass index 
(BMI), and Charlson comorbidity index correlated significantly 
with the duration of treatment. Patients who were younger, 
who had a better ECOG performance status, with no comor-
bidities, and/or who had a higher BMI were found to be on 
treatment with everolimus–exemestane for a longer duration.31
A subgroup analysis of elderly patients (70 years) was 
also presented.32 A higher proportion of elderly patients in 
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BRAWO had severe comorbidities versus nonelderly patients. 
Fewer elderly patients (46.4%) received prior CT compared 
to nonelderly patients (59.8%). The conclusion was that the 
everolimus–exemestane treatment had a manageable safety 
profile in the elderly patients and was consistent with that 
reported previously in BOLERO-2 and BALLET.32 Lower 
patient age (74 years) was significantly associated with a 
longer duration of treatment.32
Everolimus and Safety: Impact of Dose in ABC
The correlation between dose, toxicity, and outcome has been 
reported in STEPAUT and BRAWO.
STEPAUT. In STEPAUT, 40% of patients conserved a 
10 mg dose of everolimus during treatment; 28% conserved a 
5 mg dose, and 7% had dose escalation from 5 to 10 mg.20 The 
10-mg group had the longest median PFS of 9.83 months, 
while the 5-mg group had a median PFS of 4.97 months; the 
dose-escalation group had a median PFS of 6.83 months.20 
The difference between the 10-mg group and the 5-mg 
group was not statistically significant. In terms of toxic-
ity, the frequency of AE was highest in the 10-mg group in 
comparison with the 5-mg group (33.3% vs. 23.07%). The 
frequency of SAE was also the highest in the 10-mg group 
(25.64% vs. 10.25% in the 5-mg group and 5.13% in the dose-
escalation group).20
BRAWO. In BRAWO, 80.7% of patients received 
a 10-mg daily dose. Only 18.7% of patients started with a 
5-mg dose. Patients with 5 mg received a median dose inten-
sity of 50%, while those with 10 mg received a median dose 
intensity of 93.5%.23 There were no data on efficacy in the 
5-mg group. A statistically significant correlation was dem-
onstrated between everolimus starting dose and the occur-
rence of stomatitis within eight weeks—most of these were 
grades 1 and 2.33
The longer median PFS and manageable safety in patients 
receiving everolimus 10 mg versus 5 mg supports 10 mg. The 
only dosing used here was the recommended starting and 
maintenance dose in routine clinical practice. This confirms 
prior data about the optimal 10 mg daily dosing of everolimus 
with an acceptable tolerance.12,34,35
Everolimus and Safety: AEs Management in ABC
Incidence and severity of class-effect AEs observed in BC 
were comparable with phase III studies of everolimus mono-
therapy in renal cell carcinoma36,37 and pancreatic neuroendo-
crine tumor.38 There were no new or unexpected safety signals 
identified. Thus, the addition of exemestane to everolimus did 
not significantly affect its safety profile.34 However, rates of 
treatment discontinuation, and dose modifications are slightly 
higher in BOLERO-2 than in other phase III trials with 
everolimus monotherapy.34 This might be because clinicians 
were not familiar with this treatment in BC. AE may also be 
amplified in patients who received only prior ET with a more 
favorable toxicity profile.34 In addition, alternative treatment 
options for other indications might also increase the accep-
tance rate of AE.
Most AEs can be managed without treatment discon-
tinuation. It is possible to maximize treatment exposure and 
obtain the best clinical benefit for patients.34 On active moni-
toring, good patient education and a prompt identification of 
specific AEs can reduce their rate and severity and optimize 
everolimus dose intensity. Clinicians should also consider 
some everolimus-specific concerns in BC patients including 
their particular comorbidities. They are often postmenopausal 
women with diabetes, metabolic syndrome, vascular comor-
bidities, etc. Task-specific guidelines to manage AEs have 
been published to help clinicians.34,39–45
Only a few data are available to confirm the effectiveness 
of this proactive management.
In BRAWO, we already mentioned that the overall 
safety profile of everolimus–exemestane was consistent with 
that reported previously in BOLERO-2. The incidence of 
stomatitis in BRAWO (39.5%) was lower than that reported 
in BOLERO-2 (59.0%).33 The incidence of grade 3 stomatitis 
events was also lower in BRAWO (2.3%) versus BOLERO-2 
(8%).33 The majority of these stomatitis events in BRAWO 
occurred within the first eight weeks, consistent with what 
has been reported previously.33 The majority of the patients 
in BRAWO received prophylactic recommendations and 
therapeutic interventions for stomatitis management, which 
could potentially explain the lower incidence of stomatitis in 
BRAWO.33
Recently, a poster at the 2016 American Society of 
Clinical Oncology congress by Rugo et al demonstrated that 
the systematic use of an alcohol-free, steroid-based mouth-
wash significantly minimized or prevented the incidence of all 
grade, especially grade 2, stomatitis.46 This is the SWISH 
study (dexamethaSone mouthWash for everolImus-related 
stomatitiS prevention in HR+, HER2- metastatic breast 
cancer (MBC) everolimus and exemestane treatment). It was 
a multicenter, single-arm, phase II prevention trial. The inci-
dence of grade 2 stomatitis at eight weeks was 2.4% com-
pared with 33% in BOLERO-2.46 The incidence of all-grade 
stomatitis at eight weeks was 21.2%—a marked reduced inci-
dence rate versus BOLERO-2 (67%).46
Because the majority of class-effect AEs, except pneu-
monitis, had a relative short time to onset, the authors in 
BALLET recommend close follow-up in the first months 
with a first visit two weeks after starting everolimus.26
Everolimus and Safety: Relationship Between AEs 
and Efficacy
Recently, a meta-analysis was published with data from seven 
randomized, double-blind, phase III clinical trials of evero-
limus to determine the clinical impact of stomatitis on effi-
cacy and safety.47 Data were pooled from BOLERO-2 and 
BOLERO-3 (BC), RECORD-1 (renal cell carcinoma), 
RADIANT-2 (carcinoid tumors), RADIANT-3 (pancreatic 
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neuroendocrine tumors), and EXIST-1/2 (tuberous sclerosis 
complex studies). Data from solid tumor trials and tuberous 
sclerosis complex (TSC) trials were analyzed separately.47
The rate of stomatitis was 67% in the solid tumor trials 
and 70% in the TSC trials. Most stomatitis events were 
grade 1/2.47 In the solid tumor trials, 89% of first stomatitis 
episodes were observed within eight weeks.47 Patients with 
stomatitis occurring within eight weeks of everolimus initia-
tion had longer PFS than everolimus-treated patients without 
stomatitis in BOLERO-2 (8.5 vs. 6.9 months; HR = 0.78) and 
RADIANT-3 (13.9 vs. 8.3 months, HR = 0.7). A similar trend 
was observed in RECORD-1 (HR = 0.90) and RADIANT-2 
(HR = 0.87), but not in BOLERO-3 (HR = 1.01). The authors 
concluded that stomatitis did not adversely affect PFS. This 
supports the administration of everolimus in accordance with 
standard management guidelines.47
As mentioned earlier, the recent Italian retrospective 
trial in an unselected population of 181 patients was also 
conducted to evaluate a possible association between toxicity 
and response. No association between toxicity and response 
was found.27
Conclusion
Despite its toxicity profile, the addition of everolimus to 
exemestane is quite beneficial to patients with ER-positive, 
HER2-negative, ABC who progressed on prior NSAI therapy.
Most AEs are grade 1 or 2 and resolve without the need 
for treatment interruption. Moreover, the quality of life is 
better with everolimus than with placebo.
The physician’s delicate aim when treating patients with 
everolimus is to obtain a good balance between adequate man-
agement of AE and the optimization of treatment exposure. 
This is only feasible with a good knowledge of the treatment, 
a careful selection of patients (especially the older ones and 
those with comorbidities), a detailed and time-consuming but 
primordial patient’s education, and proactive monitoring fol-
lowing AE management guidelines.
The role of everolimus needs to be reevaluated in light 
of cyclin-dependent kinase inhibitors such as palbociclib with 
their own new safety profile. More than ever, clinicians must 
perfectly manage this molecule because it represents another 
weapon to circumvent endocrine resistance in ER-positive, 
HER2-negative, ABC.
The optimal sequence of combined ET with targeted 
therapy in particular in regard to the cyclin-dependent kinase 
inhibitors has yet to be determined. Cost, side effect profile, 
and disease aggressiveness at time of progression after each 
regimen should be considered when defining the specific 
treatment for each patient. Another important question is 
if all patients suffering from ER-positive, HER2-negative, 
ABC need upfront combined therapy approaches or if some 
subgroups remain candidates for endocrine monotherapy. 
Regardless, the current regimen combining everolimus and 
exemestane is an important treatment option after failure 
of NSAI therapy. Unfortunately, we cannot select a clinical 
subgroup of patients who benefit most because the treatment 
effect of adding everolimus is similar in terms of relative 
improvement across all subgroups. In addition, research on 
biomarkers was not successful. The situation is similar for 
cyclin-dependent kinase inhibitors.
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